| Nov 20 |
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
|
| Nov 14 |
CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 12 |
CG Oncology, Inc. GAAP EPS of -$0.30
|
| Nov 12 |
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 11 |
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
|
| Oct 21 |
Top small-cap stock picks from Morgan Stanley following the group's upgrade to neutral
|
| Oct 1 |
We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth
|
| Sep 16 |
CG Oncology surges 7%; seen benefitting from J&J bladder cancer asset data
|
| Sep 14 |
Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock
|
| Aug 30 |
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
